Mackenzie Financial
CORT icon

Mackenzie Financial’s Corcept Therapeutics CORT Stock Holding History

Mackenzie Financial’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-104,132
Closed -$4.2M – 1585
2026
Q1 		$4.2M Buy
+104,132
New +$3.89M 0.01% 717
2025
Q3 		– Sell
-6,768
Closed -$497K – 1733
2025
Q2 		$497K Sell
6,768
-7,387
-52% -$536K ﹤0.01% 1230
2025
Q1 		$1.62M Buy
14,155
+7,948
+128% +$484K ﹤0.01% 842
2024
Q4 		$313K Sell
6,207
-241
-4% -$12.6K ﹤0.01% 1369
2024
Q3 		$298K Hold
6,448
– – ﹤0.01% 1194
2024
Q2 		$209K Sell
6,448
-1,811
-22% -$49.6K ﹤0.01% 1323
2024
Q1 		$208K Buy
8,259
+1,811
+28% +$42.8K ﹤0.01% 1331
2023
Q4 		$209K Buy
+6,448
New +$177K ﹤0.01% 1314
2023
Q3 		– Sell
-11,697
Closed -$259K – 1493
2023
Q2 		$259K Hold
11,697
– – ﹤0.01% 1227
2023
Q1 		$253K Hold
11,697
– – ﹤0.01% 1254
2022
Q4 		$238K Buy
11,697
+766
+7% +$19.2K ﹤0.01% 1172
2022
Q3 		$280K Buy
+10,931
New +$293K ﹤0.01% 1114

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mackenzie Financial's CORT Position: Q2 2026 in Review

Mackenzie Financial sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 104,132 shares — an estimated $4.2M sold.

Mackenzie Financial first reported a position in CORT in Q3 2022 and held it in 12 quarters. The position peaked at $4.2M in Q1 2026. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Mackenzie Financial reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mackenzie Financial sold 104,132 Corcept Therapeutics shares in Q2 2026, an estimated $4.2M.
  • Mackenzie Financial first reported a position in Corcept Therapeutics in Q3 2022 and held it in 12 quarters.
  • Mackenzie Financial's Corcept Therapeutics position peaked at $4.2M in Q1 2026.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.